Literature DB >> 28941711

Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia.

Xin Zhao1, Xingmin Feng2, Zhijie Wu1, Thomas Winkler3, Ronan Desmond3, Matthew Olnes3, Bogdan Dumitriu3, Danielle M Townsley3, Cynthia E Dunbar3, Neal S Young3.   

Abstract

Although hematopoietic growth factors are found at high levels in aplastic anemia (AA) patients, little is known about their dynamic change over time after treatment. We examined plasma concentrations of hematopoietic growth factors sequentially in 55 severe AA patients, including 45 treatment-naive patients who had received immunosuppressive therapy (IST) or IST and eltrombopag, and 10 IST-refractory patients who had received eltrombopag only, focusing on thrombopoietin (TPO). TPO concentrations were much higher than normal in patients before treatment and then decreased in responders but not in nonresponders. We followed up on a cohort of nine patients who obtained stable complete remission for up to 7 years after IST and found that TPO levels declined gradually by 3 months after treatment, accompanying an increase in platelet counts, but stabilized at levels higher than normal. An inverse correlation was noted between TPO levels and platelet counts. The increased plasma TPO levels could be required to maintain normal platelet counts in remission and could also be attributed to reduced consumption by circulating platelets. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28941711      PMCID: PMC5815891          DOI: 10.1016/j.exphem.2017.09.006

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  16 in total

Review 1.  Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis.

Authors:  Ronit Gurion; Anat Gafter-Gvili; Mical Paul; Liat Vidal; Isaac Ben-Bassat; Moshe Yeshurun; Ofer Shpilberg; Pia Raanani
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

2.  Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.

Authors:  Ronan Desmond; Danielle M Townsley; Bogdan Dumitriu; Matthew J Olnes; Phillip Scheinberg; Margaret Bevans; Ankur R Parikh; Kinneret Broder; Katherine R Calvo; Colin O Wu; Neal S Young; Cynthia E Dunbar
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

3.  Criteria for severe aplastic anaemia.

Authors:  B M Camitta
Journal:  Lancet       Date:  1988-02-06       Impact factor: 79.321

4.  Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes.

Authors:  Xingmin Feng; Phillip Scheinberg; Colin O Wu; Leigh Samsel; Olga Nunez; Courtney Prince; Rebecca D Ganetzky; J Philip McCoy; Jaroslaw P Maciejewski; Neal S Young
Journal:  Haematologica       Date:  2010-12-15       Impact factor: 9.941

Review 5.  Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia.

Authors:  J C Marsh
Journal:  Semin Hematol       Date:  2000-01       Impact factor: 3.851

6.  Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization.

Authors:  R Sungaran; B Markovic; B H Chong
Journal:  Blood       Date:  1997-01-01       Impact factor: 22.113

7.  Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells.

Authors:  Hong Qian; Natalija Buza-Vidas; Craig D Hyland; Christina T Jensen; Jennifer Antonchuk; Robert Månsson; Lina A Thoren; Marja Ekblom; Warren S Alexander; Sten Eirik W Jacobsen
Journal:  Cell Stem Cell       Date:  2007-11-20       Impact factor: 24.633

8.  Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation.

Authors:  Mary J Ninan; Christopher R Flowers; John D Roback; Martha L Arellano; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2007-05-23       Impact factor: 5.742

9.  Circulating thrombopoietin levels in normal healthy blood donors and in aplastic anemia patients in relation to disease severity.

Authors:  Abhay Singh; Anupam Verma; Soniya Nityanand; Rajendra Chaudhary; Priti Elhence
Journal:  Asian J Transfus Sci       Date:  2015 Jan-Jun

10.  Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

Authors:  Connie L Erickson-Miller; Evelyne Delorme; Shin-Shay Tian; Christopher B Hopson; Amy J Landis; Elizabeth I Valoret; Teresa S Sellers; Jon Rosen; Stephen G Miller; Juan I Luengo; Kevin J Duffy; Julian M Jenkins
Journal:  Stem Cells       Date:  2009-02       Impact factor: 6.277

View more
  5 in total

1.  Aptamer-based proteomics of serum and plasma in acquired aplastic anemia.

Authors:  Valentina Giudice; Angélique Biancotto; Zhijie Wu; Foo Cheung; Julián Candia; Giovanna Fantoni; Sachiko Kajigaya; Olga Rios; Danielle Townsley; Xingmin Feng; Neal S Young
Journal:  Exp Hematol       Date:  2018-10-09       Impact factor: 3.084

Review 2.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

Review 3.  Bone Marrow Failure Syndromes, Overlapping Diseases with a Common Cytokine Signature.

Authors:  Valentina Giudice; Chiara Cardamone; Massimo Triggiani; Carmine Selleri
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

Review 4.  Novel therapeutic choices in immune aplastic anemia.

Authors:  Phillip Scheinberg
Journal:  F1000Res       Date:  2020-09-10

5.  Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag.

Authors:  Yoshitaka Zaimoku; Bhavisha A Patel; Ruba Shalhoub; Emma M Groarke; Xingmin Feng; Colin O Wu; Neal S Young
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.